top of page

The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease

Bill Sibold describes how Madrigal has prepared for the launch, visually illustrates how the medicine is meant to impact disease progression, and shares his opinion on whether GLPs could potentially compete in this indication one day in the future.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page